Lisinopril
FDA-approved product (tablet, oral), marketed as Lisinopril, Prinivil, Qbrelis and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
- Congestive heart failure
- Diabetes mellitus
- Heart failure
- Hypertension
- Myocardial infarction
- Stroke
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Ace inhibitors, plain
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA39.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis65.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Lisinopril with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment
NCT00741585 · start 2008-09-01
Registered record
- Registry ID
- NCT00741585
- Conditions
- Essential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease
- Interventions
- Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoring
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2008-09-01
- Completion
- 2018-06-30
- Enrolment
- 21,983
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEssential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney DiseaseInterventionAny antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoringPhasePhase 4Registry statusCompletedAliskiren and Renin Inhibition in Diastolic Heart Failure
NCT00773084 · start 2008-09
Registered record
- Registry ID
- NCT00773084
- Conditions
- Diastolic Heart Failure
- Interventions
- Aliskiren plus spironolactone vs. Lisinopril plus spironolactone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Withdrawn
- Start
- 2008-09
- Completion
- 2009-08
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiastolic Heart FailureInterventionAliskiren plus spironolactone vs. Lisinopril plus spironolactonePhaseNot applicableRegistry statusWithdrawnVA NEPHRON-D: Diabetes iN Nephropathy Study
NCT00555217 · start 2008-07
Registered record
- Registry ID
- NCT00555217
- Conditions
- Kidney Disease; Nephropathy; Type 2 Diabetes
- Interventions
- losartan; lisinopril
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2008-07
- Completion
- 2014-10
- Enrolment
- 1,448
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKidney Disease; Nephropathy; Type 2 DiabetesInterventionlosartan; lisinoprilPhasePhase 3Registry statusTerminatedModulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA)
NCT01181284 · start 2008-05
Registered record
- Registry ID
- NCT01181284
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2008-05
- Completion
- 2011-07
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial HypertensionInterventionNot recordedPhaseNot recordedRegistry statusCompletedResearch Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure
NCT00624065 · start 2008-03
Registered record
- Registry ID
- NCT00624065
- Conditions
- Hypertension
- Interventions
- carvedilol controlled release/lisinopril; lisinopril + placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-03
- Completion
- 2008-08
- Enrolment
- 348
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventioncarvedilol controlled release/lisinopril; lisinopril + placeboPhasePhase 3Registry statusCompletedRenal Protective Effect of ACEI and ARB in Primary Hyperoxaluria
NCT00280215 · start 2007-12
Registered record
- Registry ID
- NCT00280215
- Conditions
- Hyperoxaluria
- Interventions
- ACEI / Angiotensin converting enzyme inhibitor; ARB /Angiotensin Receptor Blocker; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Withdrawn
- Start
- 2007-12
- Completion
- 2011-12
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHyperoxaluriaInterventionACEI / Angiotensin converting enzyme inhibitor; ARB /Angiotensin Receptor Blocker; PlaceboPhasePhase 3Registry statusWithdrawnA Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure
NCT00537043 · start 2007-10
Registered record
- Registry ID
- NCT00537043
- Conditions
- Hypertension
- Interventions
- SK&F-105517 (COREG CR FDC)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-10
- Completion
- 2008-01
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionSK&F-105517 (COREG CR FDC)PhasePhase 1Registry statusCompletedA Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.
NCT00552708 · start 2007-09
Registered record
- Registry ID
- NCT00552708
- Conditions
- Hypertension
- Interventions
- COREG CR; Lisinopril
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-09
- Completion
- 2007-12
- Enrolment
- 55
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionCOREG CR; LisinoprilPhasePhase 1Registry statusCompletedThe Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients
NCT00459056 · start 2007-04
Registered record
- Registry ID
- NCT00459056
- Conditions
- Abdominal Obesity; Hypertension
- Interventions
- Carvedilol CR + Lisinopril; Lisinopril + HCTZ
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-04
- Completion
- 2010-05
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAbdominal Obesity; HypertensionInterventionCarvedilol CR + Lisinopril; Lisinopril + HCTZPhasePhase 3Registry statusCompletedReducing Total Cardiovascular Risk in an Urban Community
NCT00241904 · start 2006-05
Registered record
- Registry ID
- NCT00241904
- Conditions
- Cardiovascular Diseases; Heart Diseases; Coronary Disease; Diabetes Mellitus; Atherosclerosis; Cerebral Arteriosclerosis; Hypertension
- Interventions
- Lifestyle Changes; Antiplatelet Agents; Beta Blocker; ACE Inhibitors
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-05
- Completion
- 2010-05
- Enrolment
- 525
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiovascular Diseases; Heart Diseases; Coronary Disease; Diabetes Mellitus +3 moreInterventionLifestyle Changes; Antiplatelet Agents; Beta Blocker; ACE InhibitorsPhasePhase 4Registry statusCompletedThe Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.
NCT02336607 · start 2005-12
Registered record
- Registry ID
- NCT02336607
- Conditions
- Hypertension
- Interventions
- Felodipine tablet (Plendil) alone; Felodipine tablet (Plendil)+Hydrochlorothiazide; Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK); Felodipine tablets (Plendil)+Lisinopril (Zestril)
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-12
- Completion
- 2006-08
- Enrolment
- 529
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionFelodipine tablet (Plendil) alone; Felodipine tablet (Plendil)+Hydrochlorothiazide; Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK); Felodipine tablets (Plendil)+Lisinopril (Zestril)PhaseNot applicableRegistry statusCompletedHypertension in Hemodialysis Patients (Aim 3)
NCT00582114 · start 2005-08
Registered record
- Registry ID
- NCT00582114
- Conditions
- Hemodialysis; Hypertension; Left Ventricular Hypertrophy
- Interventions
- Lisinopril; Atenolol
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2005-08
- Completion
- 2013-09
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHemodialysis; Hypertension; Left Ventricular HypertrophyInterventionLisinopril; AtenololPhasePhase 3Registry statusTerminatedThe Canadian Prevention of Renal and Cardiovascular Endpoints Trial
NCT00231803 · start 2005-04
Registered record
- Registry ID
- NCT00231803
- Conditions
- Chronic Kidney Disease
- Interventions
- Combined CKD and CVD Prevention; Cardiovascular Disease prevention; Treatment of Chronic Kidney Disease complications; Usual care
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-04
- Completion
- 2008-06
- Enrolment
- 474
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Kidney DiseaseInterventionCombined CKD and CVD Prevention; Cardiovascular Disease prevention; Treatment of Chronic Kidney Disease complications; Usual carePhaseNot applicableRegistry statusCompletedInteraction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
NCT00631514 · start 2005-01
Registered record
- Registry ID
- NCT00631514
- Conditions
- Hypertension
- Interventions
- acetaminophen; ibuprofen; piroxicam
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2005-01
- Completion
- 2006-09
- Enrolment
- 88
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionacetaminophen; ibuprofen; piroxicamPhasePhase 4Registry statusCompletedAntiproteinuric Effect of Valsartan and Lisinopril
NCT00171574 · start 2004-11
Registered record
- Registry ID
- NCT00171574
- Conditions
- Hypertension; Diabetic Nephropathy
- Interventions
- Valsartan; Valsartan plus HCTZ; Lisinopril
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-11
- Completion
- 2006-07
- Enrolment
- 124
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertension; Diabetic NephropathyInterventionValsartan; Valsartan plus HCTZ; LisinoprilPhasePhase 4Registry statusCompleted